The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression
According to The Globe and Mail, the framework suggests: The price of generic semaglutide will start at 75% of the list price of Ozempic while only one manufacturer is approved [Source: theglobeandmail.com/business/economy/article-generic-ozempic-glp1-approved-health-canada]
Injectable Semaglutide has not been evaluated by the FDA, but side effects are expected to be similar to other Semaglutide-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)
Metabolic rates also vary from person to person